Lipo-C Injection vs Survodutide
A side-by-side research comparison of Lipo-C Injection and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Lipo-C Injection | Survodutide |
|---|---|---|
| Full name | Lipotropic MIC + B12 Injection | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Compounded medication | Phase 3 Clinical Trial |
| Mechanism | Methionine provides sulfur for detoxification, inositol supports fat transport from liver, choline emulsifies cholesterol and fat, B12 boosts cellular energy metabolism and red blood cell production. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | Combination compound | 4,500 Da (approximate) |
| Half-life | Variable by component | 5-7 days |
| Bioavailability | ~100% IM injection | High (SubQ) |
| Typical dose | 1 mL | 0.6-6.0 mg |
| Frequency | 1-2x per week | Once weekly |
| Route | Intramuscular or subcutaneous injection | Subcutaneous |
Lipo-C Injection reported benefits
- Enhanced fat metabolism
- Liver support
- Increased energy
- B12 optimization
- Complements weight loss protocols
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.